Publication

Article

CURE

Summer 2007
Volume6
Issue 4

Medicare Coverage for Colon Cancer Screenings

What does Medicare cover when it comes to screening for colorectal cancer?

>

Benefits for individuals of average risk, age 50 or older:Fecal occult blood test (FOBT), every 12 months

>

Flexible sigmoidoscopy, every 48 months

>

Screening colonoscopy, every 10 years (no minimum age)

>

Barium enema, an alternative to flexible sigmoidoscopy or colonoscopy if your physician determines its screening value is equal or better

>

Benefits for high-risk* individuals, regardless of age: FOBT, every 12 months

>

Sigmoidoscopy, every 48 months

>

Colonoscopy, every 24 months

>

Barium enema, every 24 months

>

What you’ll pay: FOBT, completely covered by Medicare

>

Flexible sigmoidoscopy, colonoscopy or barium enema, 20 percent of Medicare-approved amount after yearly Part B deductible if done in a doctor’s office (and 25 percent for a flexible sigmoidoscopy or colonoscopy done in a hospital outpatient department)

>

*You’re high risk if you have:previously had colorectal cancer

>

a close relative with colorectal polyps or cancer

>

a history of polyps

>

inflammatory bowel disease

For information about Medicare coverage of cancer screenings and about risk factors, visit www.medicare.gov/Health/cancer.asp. To learn about the Welcome to Medicare visit, see www.medicare.gov/health/physicalexam.asp.

Related Videos
Image of Dr. Fakih.
Image of Doctor with blonde hair.
Dr. Debu Tripathy discussed the importance of understanding the distinctions between HER2-low and HER2-ultralow breast cancer.
Dr. Debu Tripathy is a professor and chairman of the Department of Breast Medical Oncology, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, in Houston, and the editor-in-chief of CURE®.
Dr. Suneel Kamath is an assistant professor of medicine at the Cleveland Clinic Lerner College of Medicine of Case Western Reserve University, in Ohio.
Image of Dr. Scott Kopetz
Dr. Azka Ali is a medical oncologist at the Cleveland Clinic Taussig Cancer Institute, in Ohio.
Dr. Maxwell Lloyd, a Clinical Fellow in Medicine in the Department of Medicine at Beth Israel Deaconess Medical Center in Boston.
Dr. Maxwell Lloyd, a Clinical Fellow in Medicine, in the Department of Medicine, at Beth Israel Deaconess Medical Center in Boston.
Dr. Aditya Bardia is a professor in the Department of Medicine, Division of Hematology/Oncology, director of Translational Research Integration, and a member Signal Transduction and Therapeutics, at University of California, Los Angeles (UCLA) Health Jonsson Comprehensive Cancer Center.
Related Content